ANI Pharmaceuticals
ANIP
185 hedge funds and large institutions have $766M invested in ANI Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 73 increasing their positions, 50 reducing their positions, and 16 closing their positions.
88% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 16
46% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 50
16% more capital invested
Capital invested by funds: $662M → $766M (+$104M)
8% more funds holding
Funds holding: 171 → 185 (+14)
4% more ownership
Funds ownership: 61.09% → 65.09% (+4%)
15% less call options, than puts
Call options by funds: $1.65M | Put options by funds: $1.96M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$21.2M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$12.7M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$10.4M |
| 4 |
Charles Schwab
San Francisco,
California
|
+$6.29M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$7.71M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$6.58M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$5.3M |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$4.71M |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$4.47M |
ANIP Hedge Fund Activity: Q3 2023 in Review
185 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q3 2023, worth a combined $766M — up 16% from $662M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ANIP positions and 16 closed out — a net gain of 14 holders — while 73 added to existing stakes and 50 trimmed.
The largest buyer was BlackRock, adding an estimated $21.2M. The largest seller was Thompson Siegel & Walmsley, cutting an estimated $7.71M.
- 185 institutional investors held ANI Pharmaceuticals (ANIP) as of Q3 2023, up from 171 in Q2 2023.
- Funds reported $766M of ANI Pharmaceuticals stock for Q3 2023, up 16% quarter-over-quarter.
- 30 funds opened new ANI Pharmaceuticals positions in Q3 2023 and 16 closed out, a net change of +14 holders.
- The largest ANI Pharmaceuticals buyer in Q3 2023 was BlackRock, an estimated $21.2M added.
- The largest ANI Pharmaceuticals seller in Q3 2023 was Thompson Siegel & Walmsley, an estimated $7.71M sold.
Based on aggregated 13F filings for Q3 2023.